Risk factors assessment and therapeutic drug management of sars covid-19 virus
Abstract
Severe acute respiratory syndrome corona virus (COV)-2(SARS-COV-2) previously called 2019 novel cov emerged from china. This virus causes cov disease-19(COVID-19), favipiravir (1000mg) is an oral anti-viral that inhibits RNA polymerase that is a pproved in Russia during phase 2/3 clinical trials for the treatment of covid. Ivermectin an antiparasitic drug showed an in-vitro reduction of viral RNA in vero-hslam cells 2hr post-infection with SARS-COV-2.corticosteroids include dexamethasone (6mg), Methyl Prednisolone (80mg) can induce harm through immunosuppressant effects during treatment of infection and a study in the Netherlands showed a 5-day course of high dose corticosteroids accelerated respiratory recovery lowered hospital mortality rates and reduced the likelihood of mechanical ventilation in patients with severe COVID-19 associated cytokine storm syndrome. Use of convalescent PLASMA after a multicentre study conducted by Mayo clinic indicates transfusion of ABO-compatible human covid-19 is safe and effective in hospitalized adults. NAK and JAK inhibitors may mitigate systemic and alveolar inflammation in patience with covid-19 pneumonia by inhibiting essential cytokine signaling drugs include baricitinib (4mg), fedratinib (100mg), ruxolitinib (5mg). Statins decrease the inflammatory processes of atherosclerosis. Vitamins and mineral supplements have been promoted for the treatment of respiratory viral infections. Hydroxychloroquine(400mg) and chloroquine (600mg) are widely used anti-malarial drugs that elicit immunomodulatory effects based on PBPK models recommended loading dose of HCQ is 400mg (BID) followed by 200mg (BID) for four days. In a randomized controlled, open-label trial of hospitalized adults with conformed SARSCOV-2, recruited patients had 02 saturation of 94% less than ambient air or pao2 of less than 300mmhg were randomized to receive Lopinavir/Ritonavir 400mg/100mg for 14 days, Adjunctive nutritional therapies also recommended.
Downloads
References
2. N. Zhu, D. Zhang, W. Wang, et al.A novel coronavirus from patients with pneumonia in China, 2019,N. Engl. J. Med. (2020).
3. J. Fang, L. Deng, L. Zhang, Y. Cai, C.W. Cheung, Z. XiaReview of the clinical characteristics of coronavirus disease 2019 (COVID-19),J. Gen. Intern. Med. (2020).
4. C.I. Paules, H.D. Marston, A.S. FauciCoronavirus infections—more than just the common cold, JAMA (2020).
5. World Health OrganizationCoronavirus Disease 2019 (COVID-19) Situation Report – 36, (2020).
6. F. Wu, S. Zhao, B. Yu, et al.A new coronavirus associated with human respiratory disease in China, Nature., 579 (2020), pp. 265-269.
7. R. Lu, Z. Zhao, J. Li, et al.Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395 (2020), pp. 565-574.
8. P. Qin, E.Z. Du, W.T. Luo, et al.Characteristics of the life cycle of porcine deltacoronavirus (PDCoV) in vitro: replication kinetics, cellular ultrastructure and virion morphology, and evidence of inducing autophagy, Viruses, 11 (2019), p. 455
9. Z. QinfenThe life cycle of SARS coronavirus in Vero E6 cells,J. Med. Virol., 73 (3) (2004), pp. 332-337.
10. F. LiStructure, function, and evolution of coronavirus spike proteins, Ann. Rev. Virol., 3 (2016), pp. 237-261.
11. https:\\www.ncbi.nlm.nih.gov
12. https:\\www.science direct.com
13. https:\\www.webmd.com
14. Medscape articles on therapeutic management of covid-19.
15. 16. https://dx.doi.org/10.1016%2Fj.dsx.2020.05.018.
Copyright © Author(s) retain the copyright of this article.
jbn520@gmail.com


.